146 related articles for article (PubMed ID: 3346542)
21. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
DiLillo DJ; Pawluczkowycz AW; Peng W; Kennedy AD; Beum PV; Lindorfer MA; Taylor RP
Mol Immunol; 2006 Mar; 43(7):1010-9. PubMed ID: 15961157
[TBL] [Abstract][Full Text] [Related]
22. Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells.
Lambré CR; Kazatchkine MD; Maillet F; Thibon M
J Immunol; 1982 Feb; 128(2):629-34. PubMed ID: 6459381
[TBL] [Abstract][Full Text] [Related]
23. Binding of choleragen and anti-ganglioside antibodies to gangliosides incorporated into preformed liposomes.
Richards RL; Fishman PH; Moss J; Alving CR
Biochim Biophys Acta; 1983 Sep; 733(2):249-55. PubMed ID: 6882761
[TBL] [Abstract][Full Text] [Related]
24. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Oct; 131(4):1930-5. PubMed ID: 6225800
[TBL] [Abstract][Full Text] [Related]
25. Control of the immune complex-complement interaction by protein H of the alternative complement pathway and the natural inhibitor heparin.
Spycher MO; Nydegger UE
Eur J Immunol; 1984 Mar; 14(3):276-9. PubMed ID: 6231187
[TBL] [Abstract][Full Text] [Related]
26. Activation of the alternative pathway of human complement by the extracellular slime glycolipoprotein of Pseudomonas aeruginosa.
Lambris J; Papamichail M; Ioannidis C; Dimitracopoulos G
J Infect Dis; 1982 Jan; 145(1):78-82. PubMed ID: 6798132
[TBL] [Abstract][Full Text] [Related]
27. [Alternative complement pathway].
Jouvin MH; Kazatchkine M
Sem Hop; 1984 May; 60(19):1371-8. PubMed ID: 6326330
[TBL] [Abstract][Full Text] [Related]
28. Volcanic ash and human complement.
Olenchock SA; Mull JC
Life Sci; 1981 Feb; 28(7):791-4. PubMed ID: 6262591
[No Abstract] [Full Text] [Related]
29. Solubilization of immune precipitates by six isolated alternative pathway proteins.
Fujita T; Takata Y; Tamura N
J Exp Med; 1981 Dec; 154(6):1743-51. PubMed ID: 6459396
[TBL] [Abstract][Full Text] [Related]
30. Antibody-independent activation of the alternative complement pathway by measles virus-infected cells.
Sissons JG; Oldstone MB; Schreiber RD
Proc Natl Acad Sci U S A; 1980 Jan; 77(1):559-62. PubMed ID: 6928644
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway.
Boackle RJ; Caughman GB; Vesely J; Medgyesi G; Fudenberg HH
Mol Immunol; 1983 Nov; 20(11):1157-64. PubMed ID: 6228720
[TBL] [Abstract][Full Text] [Related]
32. Identification of peptidic inhibitors of the alternative complement pathway based on Staphylococcus aureus SCIN proteins.
Summers BJ; Garcia BL; Woehl JL; Ramyar KX; Yao X; Geisbrecht BV
Mol Immunol; 2015 Oct; 67(2 Pt B):193-205. PubMed ID: 26052070
[TBL] [Abstract][Full Text] [Related]
33. Interaction of antimicrobial peptide magainin 2 with gangliosides as a target for human cell binding.
Miyazaki Y; Aoki M; Yano Y; Matsuzaki K
Biochemistry; 2012 Dec; 51(51):10229-35. PubMed ID: 23194027
[TBL] [Abstract][Full Text] [Related]
34. Engineering complement activation on polypropylene sulfide vaccine nanoparticles.
Thomas SN; van der Vlies AJ; O'Neil CP; Reddy ST; Yu SS; Giorgio TD; Swartz MA; Hubbell JA
Biomaterials; 2011 Mar; 32(8):2194-203. PubMed ID: 21183216
[TBL] [Abstract][Full Text] [Related]
35. [The C3 activating capacity in human serum--measured as monocyte mediated chemiluminescence].
Ernst M; Ennen J; Flad HD
Immun Infekt; 1984 Feb; 12(1):35-6. PubMed ID: 6241919
[TBL] [Abstract][Full Text] [Related]
36. Gangliosides can activate human alternative complement pathway.
Oshima H; Soma G; Mizuno D
Int Immunol; 1993 Oct; 5(10):1349-51. PubMed ID: 8268140
[TBL] [Abstract][Full Text] [Related]
37. Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement.
Schreiber RD; Pangburn MK; Medicus RG; Müller-Eberhard HJ
Clin Immunol Immunopathol; 1980 Mar; 15(3):384-96. PubMed ID: 6899978
[No Abstract] [Full Text] [Related]
38. Methylprednisolone inhibits the alternative and amplification pathways of complement.
Weiler JM; Packard BD
Infect Immun; 1982 Oct; 38(1):122-6. PubMed ID: 6754609
[TBL] [Abstract][Full Text] [Related]
39. Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages.
Kipnis TL; David JR; Alper CA; Sher A; da Silva WD
Proc Natl Acad Sci U S A; 1981 Jan; 78(1):602-5. PubMed ID: 6454138
[TBL] [Abstract][Full Text] [Related]
40. Antibody dependent, complement mediated liver uptake of liposomes containing GM1.
Liu D; Song YK; Liu F
Pharm Res; 1995 Nov; 12(11):1775-80. PubMed ID: 8592685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
